Simona Saporiti

Dr. Simona Saporiti

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2021 in Biophysical Journal
Verified
Journal Article
Closed access
SSSimona Saporiti
Simona Saporiti
CPChiara Parravicini
Chiara Parravicini
CPCarlo Pergola
Carlo Pergola
UGUliano Guerrini
Uliano Guerrini
MRMara Rossi
Mara Rossi
IEIvano Eberini
Ivano Eberini

Verified
Journal Article
Open access
PDF file
TLTommaso Laurenzi
Tommaso Laurenzi
LPLuca Palazzolo
Luca Palazzolo
ETElisa Taiana
Elisa Taiana
SSSimona Saporiti
Simona Saporiti
OMOmar Ben Mariem
Omar Ben Mariem
IEIvano Eberini
Ivano Eberini
NONO and SFPQ are involved in multiple nuclear processes (e.g., pre-mRNA splicing, DNA repair, and transcriptional regulation). These proteins, along with NEAT1, enable paraspeckle formation, thus promoting multiple myeloma cell survival. In this paper, we investigate NONO and SFPQ dimer stability, highlighting the hetero- and homodimer structural differences, and model their interactions with RNA, simulating their binding to a polyG probe mimicking NEAT1guanine-rich regions. We demonstrated in silico that NONO::SFPQ heterodimerization is a more favorable process than homodimer formation. We also show that NONO and SFPQ RRM2 subunits are primarily required for protein–protein interactions with the other DBHS protomer. Simulation of RNA binding to NONO and SFPQ, beside validating RRM1 RNP signature importance, highlighted the role of β2 and β4 strand residues for RNA specific recognition. Moreover, we demonstrated the role of the NOPS region and other protomer’s RRM2 β2/β3 loop in strengthening the interaction with RNA. Our results, having deepened RNA and DBHS dimer interactions, could contribute to the design of small molecules to modulate the activity of these proteins. RNA-mimetics, able to selectively bind to NONO and/or SFPQ RNA-recognition site, could impair paraspeckle formation, thus representing a first step towards the discovery of drugs for multiple myeloma treatment.

3 March 2023 in Communications Biology
Verified
Journal Article
Open access
PDF file
SSSimona Saporiti
Simona Saporiti
TLTommaso Laurenzi
Tommaso Laurenzi
UGUliano Guerrini
Uliano Guerrini
CCCrescenzo Coppa
Crescenzo Coppa
WPWolf Palinsky
Wolf Palinsky
IEIvano Eberini
Ivano Eberini
N-glycosylation plays a key role in modulating the bioactivity of monoclonal antibodies (mAbs), as well as the light chain (LC) isotype can influence their physicochemical properties. However, investigating the impact of such features on mAbs conformational behavior is a big challenge, due to the very high flexibility of these biomolecules. In this work we investigate, by accelerated molecular dynamics (aMD), the conformational behavior of two commercial immunoglobulins G1 (IgG1), representative of κ and λ LCs antibodies, in both their fucosylated and afucosylated forms. Our results show, through the identification of a stable conformation, how the combination of fucosylation and LC isotype modulates the hinge behavior, the Fc conformation and the position of the glycan chains, all factors potentially affecting the binding to the FcγRs. This work also represents a technological enhancement in the conformational exploration of mAbs, making aMD a suitable approach to clarify experimental results.

23 December 2022 in Proteins: Structure, Function, and Bioinformatics
Verified
Journal Article
Closed access
OMOmar Ben Mariem
Omar Ben Mariem
SSSimona Saporiti
Simona Saporiti
UGUliano Guerrini
Uliano Guerrini
TLTommaso Laurenzi
Tommaso Laurenzi
LPLuca Palazzolo
Luca Palazzolo
IEIvano Eberini
Ivano Eberini

3 June 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
OMOmar Ben Mariem
Omar Ben Mariem
LPLuca Palazzolo
Luca Palazzolo
BTBeatrice Torre
Beatrice Torre
YWYao Wei
Yao Wei
DBDavide Bianchi
Davide Bianchi
IEIvano Eberini
Ivano Eberini
The Organic Cation Transporter Novel 1 (OCTN1), also known as SLC22A4, is widely expressed in various human tissues, and involved in numerous physiological and pathological processes remains. It facilitates the transport of organic cations, zwitterions, with selectivity for positively charged solutes. Ergothioneine, an antioxidant compound, and acetylcholine (Ach) are among its substrates. Given the lack of experimentally solved structures of this protein, this study aimed at generating a reliable 3D model of OCTN1 to shed light on its substrate-binding preferences and the role of sodium in substrate recognition and transport. A chimeric model was built by grafting the large extracellular loop 1 (EL1) from an AlphaFold-generated model onto a homology model. Molecular dynamics simulations revealed domain-specific mobility, with EL1 exhibiting the highest impact on overall stability. Molecular docking simulations identified cytarabine and verapamil as highest affinity ligands, consistent with their known inhibitory effects on OCTN1. Furthermore, MM/GBSA analysis allowed the categorization of substrates into weak, good, and strong binders, with molecular weight strongly correlating with binding affinity to the recognition site. Key recognition residues, including Tyr211, Glu381, and Arg469, were identified through interaction analysis. Ach demonstrated a low interaction energy, supporting the hypothesis of its one-directional transport towards to outside of the membrane. Regarding the role of sodium, our model suggested the involvement of Glu381 in sodium binding. Molecular dynamics simulations of systems at increasing levels of Na+ concentrations revealed increased sodium occupancy around Glu381, supporting experimental data associating Na+ concentration to molecule transport. In conclusion, this study provides valuable insights into the 3D structure of OCTN1, its substrate-binding preferences, and the role of sodium in the recognition. These findings contribute to the understanding of OCTN1 involvement in various physiological and pathological processes and may have implications for drug development and disease management.

15 December 2023 in Glycoconjugate Journal
Verified
Journal Article
Closed access
PDF file
Maria FazzariMaria Fazzari
Maria Fazzari
Giulia LunghiGiulia Lunghi
Giulia Lunghi
EBErika Di Biase
Erika Di Biase
MMMargherita Maggioni
Margherita Maggioni
Emma Veronica CarsanaEmma Veronica Carsana
Emma Veronica Carsana
Sandro SonninoSandro Sonnino
Sandro Sonnino